Valuation: AbbVie Inc.

Market Cap 440B 381B 357B 326B 613B 41,954B 623B 4,206B 1,642B 21,001B 1,650B 1,615B 70,058B P/E 2026 *
31.8x
P/E 2027 * 23.5x
Enterprise Value 500B 433B 406B 370B 697B 47,712B 708B 4,783B 1,867B 23,883B 1,877B 1,836B 79,672B EV / Sales 2026 *
7.4x
EV / Sales 2027 * 6.68x
Free-Float
95.71%
Yield 2026 *
2.76%
Yield 2027 * 2.9%
1 day+0.72%
1 week+0.94%
Current month-2.28%
1 month-0.28%
3 months+21.63%
6 months+14.46%
Current year+10.00%
1 week 210.6
Extreme 210.6
216.5
1 month 210
Extreme 210
234.4
Current year 167.55
Extreme 167.55
234.4
1 year 167.55
Extreme 167.55
234.4
3 years 125.5
Extreme 125.5
234.4
5 years 89.89
Extreme 89.89
234.4
10 years 50.18
Extreme 50.183
234.4
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.69%+0.94% - - 440B
-0.92%+3.35%+89.07%+128.86% 1,088B
+0.47%+1.74%+51.68%+50.75% 629B
+0.83%+1.88%+26.27%+64.82% 440B
-0.88%-0.66%+47.04%+36.64% 359B
-0.37%-0.58%+28.59%+36.31% 291B
+0.05%-2.73%+5.61%+6.15% 245B
+0.40%+2.45%+46.62%+59.17% 225B
-0.42%+1.34%-6.94%-51.94% 204B
+1.67%+4.84%+15.10%+72.68% 168B
Average +0.27%+1.27%+33.67%+44.82% 405.47B
Weighted average by Cap. +0.06%+1.93%+49.09%+65.97%

Financials

2026 *2027 *
Net sales 67.58B 58.58B 54.92B 50.07B 94.22B 6,450B 95.73B 647B 252B 3,229B 254B 248B 10,771B 73.51B 63.72B 59.73B 54.46B 102B 7,016B 104B 703B 275B 3,512B 276B 270B 11,716B
Net income 13.86B 12.02B 11.26B 10.27B 19.32B 1,323B 19.63B 133B 51.78B 662B 52.04B 50.91B 2,209B 18.9B 16.38B 15.36B 14B 26.35B 1,804B 26.77B 181B 70.6B 903B 70.96B 69.42B 3,012B
Net Debt 60.33B 52.29B 49.02B 44.7B 84.1B 5,758B 85.45B 577B 225B 2,882B 226B 222B 9,615B 51.47B 44.61B 41.82B 38.13B 71.75B 4,912B 72.9B 492B 192B 2,459B 193B 189B 8,203B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-08-13 214.50 -0.69% 50
26-08-12 €216.00 -0.14% 58
26-08-11 €216.30 +1.45% 79
26-08-10 €213.20 +0.24% 755
26-08-07 €212.70 +0.71% 8
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
248.76USD
Average target price
276.24USD
Spread / Average Target
+11.05%

Quarterly revenue - Rate of surprise